BMO Capital Has Just Reaffirmed $206 Target Price Per Share on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock, While They’ve Also Reiterated Their Outperform Rating

August 9, 2018 - By Vernon Prom

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Investors sentiment decreased to 1.02 in Q1 2018. Its down 0.07, from 1.09 in 2017Q4. It worsened, as 29 investors sold Jazz Pharmaceuticals plc shares while 96 reduced holdings. 44 funds opened positions while 84 raised stakes. 51.95 million shares or 1.94% less from 52.98 million shares in 2017Q4 were reported.

Sei holds 9,698 shares. Td Asset Mngmt Inc holds 47,291 shares or 0.01% of its portfolio. Moreover, Lsv Asset Management has 0.06% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 230,670 shares. Mitsubishi Ufj Holdings Company has invested 0.02% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Ajo Lp reported 0.13% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Shaker Invs Ltd Oh holds 0.37% or 3,962 shares in its portfolio. State Street Corp holds 683,050 shares. San Francisco Sentry Investment Group (Ca) reported 0% stake. British Columbia Investment Mngmt accumulated 0.03% or 22,542 shares. Northwestern Mutual Wealth Co has 242 shares. 6,158 are held by Highstreet Asset. Daiwa Group owns 2,331 shares for 0% of their portfolio. Franklin Street Advisors Inc Nc holds 0.05% or 2,280 shares in its portfolio. Vanguard stated it has 0.03% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). X Co holds 0% or 208 shares.

Since February 14, 2018, it had 0 buys, and 23 sales for $5.70 million activity. $27,998 worth of stock was sold by MILLER MICHAEL PATRICK on Wednesday, February 14. Young Matthew P. sold $105,854 worth of stock. 877 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares with value of $122,446 were sold by Treacy Paul. WILSON KAREN J also sold $604,345 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Tuesday, April 10.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reaffirmed

New York: In analysts note issued on 8 August, BMO Capital maintained their Outperform rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) shares. They now have a $206 target price on the firm. BMO Capital’s target would indicate a potential upside of 18.44 % from the company’s last stock close.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 12 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Jazz Pharmaceuticals has $21900 highest and $16000 lowest target. $192.45’s average target is 10.64% above currents $173.935 stock price. Jazz Pharmaceuticals had 19 analyst reports since February 20, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of JAZZ in report on Wednesday, February 28 with “Buy” rating. FBR Capital maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Friday, March 9 with “Buy” rating. Leerink Swann maintained the stock with “Buy” rating in Friday, March 16 report. As per Monday, March 19, the company rating was upgraded by Morgan Stanley. The firm has “Buy” rating by Bank of America given on Tuesday, February 20. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, July 11. The firm has “Buy” rating given on Tuesday, July 10 by Citigroup. As per Friday, March 23, the company rating was maintained by H.C. Wainwright. Seaport Global maintained it with “Buy” rating and $17500 target in Friday, April 6 report. FBR Capital maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Thursday, May 10 with “Buy” rating.

The stock decreased 0.94% or $1.645 during the last trading session, reaching $173.935. About 18,113 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has risen 8.53% since August 9, 2017 and is uptrending. It has underperformed by 4.04% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $10.49 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 23.82 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Benzinga.com which released: “10 Biggest Price Target Changes For Wednesday” on August 08, 2018, also Benzinga.com with their article: “8 Stocks Moving In Tuesday’s After-Hours Session” published on August 07, 2018, Benzinga.com published: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Streetinsider.com and their article: “Pre-Open Movers 08/08: (AAOI) (DDD) (MTCH) Higher; (AMPE) (EXTR) (FTK) Lower (more…)” published on August 08, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” with publication date: August 07, 2018.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.